METHOD OF QUANTIFICATION OF AMANTADINE IN BLOOD PLASMA Russian patent published in 2018 - IPC G01N33/49 G01N33/50 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely to clinical pharmacology, and is intended for the quantification of amantadine in blood plasma. For the quantification of amantadine in blood plasma, a blood test is performed by chromatography-mass spectrometry. Chromatography-mass spectrometry is carried out using a matrix in the form of blood plasma with amantadine and an internal standard – a substance similar in the molecular structure to the analyte – N-adamantyl-hexamethyleneimine. Separation of the extraction products is carried out on a reverse phase chromatographic column 4.6×100 mm, filled with fine-pored octadecylsilyl silica gel with a particle size of 5 mcm. 10 mM ammonium acetate solution A and a mixture of acetonitrile and 10 mM ammonium acetate in a ratio of 90:10 solution B in the ratio A:B to 42:58 are used as eluent. Separation of the extraction products is carried out with a separation temperature of 30 °C and the eluent flow rate is 0.6 ml/min. Detection of the internal standard is carried out with respect to a daughter ion with m/z 134.9, formed as a result of fragmentation of a parent molecular ion with m/z 234.0. Detection of amantadine is carried out on the daughter ion with m/z 134.9, formed as a result of fragmentation of the parent molecular amantadine with m/z 152.0 at a normalized collision energy of 20 eV, and its concentration is calculated by the formula: C=1198, 5306×AR, where C is the concentration of amantadine (mcg/ml), AR is the ratio of the area of the chromatographic peak of amantadine to the peak area of the internal standard.

EFFECT: method provides high reproducibility and accuracy of the quantification of amantadine in blood plasma.

1 cl, 4 dwg, 1 tbl